Searchable abstracts of presentations at key conferences in endocrinology

ea0056p147 | Neuroendocrinology | ECE2018

Ectopic cushing’s syndrome: Six cases description

Zunzunegui Nerea Egana , Garay Ismene Bilbao , Cordeu Maite Perez de Ciriza , Iregi Izaskun Olaizola , Calafell Maite Aramburu , Diaz Leire Agea , Delgado Cristina Garcia , Arrieta Alfredo Yoldi , Iglesias Miguel Maria Goena

Introduction: Ectopic Cushing’s syndrome (ECS) is due to ACTH secretion of no pituitary neuroendocrine tumors and represents around 5–10% of all cases of ACTH dependent Cushing’s syndromes.Methods: Six cases of ECS diagnosticated from 2008 to 2017 were studied. Patients’ age ranges from 36 to 69 years (mean 53), four females and two males. Three had pancreatic tumors, two small cell lung carcinomas and one pheocromocytoma. At diagnosi...

ea0073pep6.2 | Presented ePosters 6: Calcium and Bone | ECE2021

Yes associated protein 1 (YAP1) expression and modulation by calcium sensing receptor activation in human parathyroid tumors

Tavanti Giulia Stefania , Verdelli Chiara , Maroni Paola , Guarnieri Vito , Scillitani Alfredo , Silipigni Rosamaria , Guerneri Silvana , Maggiore Riccardo , Mari Gilberto , Vicentini Leonardo , Ciaramella Paolo Dalino , Morotti Annamaria , Vaira Valentina , Corbetta Sabrina

The Hippo pathway is involved in human tumorigenesis and regeneration. Here, we investigated the Hippo co-activator YAP1 and the kinase LATS1/2 in tumors of the parathyroid glands, which are almost invariably associated with primary hyperparathyroidism. Compared with normal parathyroid glands (n = 3), where YAP1 was detectable in the cytoplasm and in the nucleus, parathyroid adenomas (PAds; n = 10) had YAP1 accumulation mainly at the nuclear level, while in p...

ea0073aep642 | Thyroid | ECE2021

Estimating risk of recurrence of differentiated thyroid cancer patients: a real-world multicenter validation of the american thyroid association initial risk stratification and dynamic re-assessment after 5 years of follow-up.

Cera Gianluca , Grani Giorgio , Puxeddu Efisio , Arvat Emanuela , Pontecorvi Alfredo , Pio Lombardi Celestino , Torlontano Massimo , Chiara Zatelli Maria , Antonelli Alessandro , Tallini Giovanni , GRAZIA CASTAGNA MARIA , Fugazzola Laura , Filetti Sebastiano , Durante Cosimo

BackgroundMost Differentiated Thyroid Cancer (DTC) cases typically show indolent biological behavior and a low mortality rate. Various prognostic systems are used to assess disease recurrence risk, to tailor treatment and follow-up strategies. The initial Risk Stratification System (RSS) and dynamic Response to Therapy Re-stratification (RTR) system, recommended by the 2015 American Thyroid Association (ATA) Guidelines, are the most employed. Still, they...

ea0073aep703 | Thyroid | ECE2021

Collision tumor of the thyroid: follicular thyroid carcinoma plus metastatic renal cell carcinoma

Cristina Elías Ortega , Venegas Nebreda Inmaculada , Maria Teresa Aramburu Calafell , Nerea Egaña Zunzunegui , Bilbao Garay Ismene , Garcia Delgado Cristina , Aguirre Echevarria Pablo , Rojo Alvaro Jorge , Yoldi Arrieta Alfredo , Miguel Maria Goena Iglesias

IntroductionThe term collision tumor refers to the coexistence of two histologically distinct malignant neoplasms. The two malignancies can originate from the same organ or occur as metastases from other regions. This type of tumors involving the thyroid gland are especially rare. Reported cases are usually involving papillary thyroid carcinomas in coexistence with other types of tumors like medullary carcinoma, follicular carcinoma or metastasic disease...

ea0073ep152 | Pituitary and Neuroendocrinology | ECE2021

Management of malignant insulina

Nerea Egaña Zunzunegui , Elias Ortega Cristina , Venegas Nebreda Inmaculada , Bilbao Garay Ismene , Aramburu Calafell Maite , Cristina García Delgado , Rojo Alvaro Jorge , Maite Perez de Ciriza Cordeu , Yoldi Arrieta Alfredo , Miguel Maria Goena Iglesias

IntroductionMalignant insulinoma is a rare pancreatic neuroendocrine tumor that accounts for only 10% of all cases of insulinoma. The clinical picture is characterized by the presence of severe hyperinsulinemic hypoglycaemic syndrome in a patient with pancreatic tumor with locoregional and/or distant metastases. Therapeutic management is challenging due to the need to control both hypoglycemic syndrome and tumor growth. Curative surgery is rarely applica...

ea0006s12 | Gaseous signalling | SFE2003

THE HEME OXYGENASE-CARBON MONOXIDE PATHWAY IN THE CONTROL OF NEUROENDOCRINE FUNCTION

Grossman A

The gases nitric oxide (NO) and carbon monoxide (CO) function as intercellular messengers in a completely novel manner, providing a medium of cellular communication quite distinct from the classical neuroregulators. These agents will diffuse according to their physicochemical characteristics, in evanescent 'puffs' with spherical limits, unconstrained by formal cell boundaries. Most work has concentrated on their roles in inflammation and control of the vascular tree, but there...

ea0090oc9.3 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Prolonged exposure to target mitotane concentrations is associated with better recurrence-free survival in patients with adrenocortical carcinoma on adjuvant treatment

Puglisi Soraya , Calabrese Anna , Basile Vittoria , Kimpel Otilia , Altieri Barbara , Angelousi Anna , Kaltsas Gregory , Ambroziak Urszula , Appetecchia Marialuisa , Arosio Maura , Berruti Alfredo , Cosentini Deborah , Canu Letizia , Ceccato Filippo , Dalmazi Guido Di , Bouys Lucas , Libe Rossella , Papierska Lucyna , Pittaway James , Kienitz Tina , Quinkler Marcus , Elhassan Yasir , Ronchi Cristina , Saiegh Leonard , Stigliano Antonio , Dusek Tina , Kastelan Darko , Fassnacht Martin , Terzolo Massimo

Background: The management of adjuvant mitotane therapy in patients with adrenocortical carcinoma (ACC) is challenging. Plasma mitotane concentrations>14 mg/l have been associated with efficacy in the treatment of advanced ACC; however, data in the adjuvant setting are mixed. Moreover, there is no consensus on how to assess the optimal exposure to mitotane and all the proposed methods have inherent limitations. We have recently proposed a new method analogous to what is es...

ea0063gp139 | Obesity | ECE2019

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

Luzi Livio , Raben Anne , Astrup Arne , Matejkova Erika , Svacina Stepan , Gnessi Lucio , Navas-Carretero Santiago , Martinez J Alfredo , Greenway Frank , Aronne Louis , Apovian Caroline , Kaplan Lee , Hill James , Fujioka Ken , Still Christopher , Sannino Alessandro , Saponaro Cosimo , Calderon Henry , Urban Lorien , Chiquette Elaine , Leider Harry , Ron Eyal , Zohar Yishai , Heshmati Hassan

Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...

ea0049gp33 | Bone & Calcium Homeostasis 1 | ECE2017

“Hyperparanet”: a multicenter Italian study on Primary Hyperparathyroidism

Saponaro Federica , Cetani Filomena , Camozzi Valentina , D'Angelo Antonella , Minisola Salvatore , Scillitani Alfredo , Cipri Claudia , Palmieri Serena , Chiodini Iacopo , Romanelli Francesco , Madeo Bruno , Castellano Elena , Gianotti Laura , Faggiano Antongiulio , Cianferotti Luisella , Brandi Maria Luisa , Corbetta Sabrina , De Feo Maria Laura , Palermo Andrea , Marcocci Claudio

The aim of the present study was to evaluate the phenotype of PHPT, the adherence to International Guidelines and the rate of surgical cure of PHPT in Italy. From January 2014–January 2016, we conducted a prospective, multicenter (n=29 endocrine tertiary referral centers) study on patients with PHPT, recording clinical and biochemical data, parathyroid imaging and therapy choice at baseline and at last follow-up. The study group included 604 patients with PHPT, w...

ea0049gp231 | Thyroid Cancer | ECE2017

Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study

Mazziotti Gherardo , Panarotto Maria Beatrice , Arvat Emanuela , Chiti Arturo , Cuocolo Alberto , Dottorini Massimo , Elisei Rossella , Filetti Sebastiano , Filice Angelina , Formenti Anna Maria , Pace Leonardo , Pellegrino Teresa , Nodari Marcello , Salvatori Massimo , Tranfaglia Cristina , Versari Annibale , Frara Stefano , Berruti Alfredo , Giustina Andrea , Giubbini Raffaele

Although differentiated thyroid cancer (DTC) has the third highest propensity to spread to the bone after breast and prostate cancer, there is a paucity of data concerning the treatment of bone metastasis (BM) in this setting. The MOSCATI (Metastasi OSsee da Carcinoma TIroideo) was a multicenter, retrospective study investigating the real-life outcome and management of BM in 143 patients (80 F, 63 M; median age 60 years) with DTC involving 10 specialized cente...